Eyes on the Prize : Decoding the Ophthalmic Product Regulations and Intricacies of the U.S. Food and Drug Administration Approval
The dynamic and continuously evolving field of ophthalmology necessitates rigorous regulatory oversight in the United States. This review outlines the multifaceted Food and Drug Administration's (FDA) approval process for ophthalmic products, detailing the classifications, pathways, and regulatory compliance for devices, drugs, biologics, and combination products. Particular emphasis is placed on distinct frameworks for Class I, II, and III devices, as well as regulations for drugs, biologics, and combination products. The organizational structure of the FDA is detailed, with highlights on specific Ophthalmology oversight divisions, historical regulatory evolution, and initiatives such as Patient-Focused Drug Development. An in-depth examination of the regulatory journey, ranging from initial research to post-marketing surveillance, includes practical guidance through stages such as Pre-Investigational New Drug/Pre-Submission consultations, clinical trials, new drug application/biologics license application/premarket approval submissions, and FDA advisory committee interactions. The article underscores the importance of early interactions with the health authorities, interdisciplinary team collaboration, adherence to current standards, and the anticipation of policy changes to ensure patient safety. It concludes with an analysis of 4 key FDA-approved ophthalmic products, including Eylea®, Luxturna®, Alphagan P®, and the Raindrop® Near Vision Inlay, detailing their contributions to ophthalmic care and offering valuable insights into their respective clinical trials, regulatory pathways, and potential implications. These case studies are included to illustrate both successful and failed ophthalmic product launches, thereby highlighting the importance of alignment with regulatory compliance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics - 39(2023), 8 vom: 03. Okt., Seite 572-582 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hirani, Khemraj [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Age-related macular degeneration |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 27.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1089/jop.2023.0071 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362908745 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362908745 | ||
| 003 | DE-627 | ||
| 005 | 20231226092226.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/jop.2023.0071 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1209.xml |
| 035 | |a (DE-627)NLM362908745 | ||
| 035 | |a (NLM)37797226 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hirani, Khemraj |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Eyes on the Prize |b Decoding the Ophthalmic Product Regulations and Intricacies of the U.S. Food and Drug Administration Approval |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 27.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The dynamic and continuously evolving field of ophthalmology necessitates rigorous regulatory oversight in the United States. This review outlines the multifaceted Food and Drug Administration's (FDA) approval process for ophthalmic products, detailing the classifications, pathways, and regulatory compliance for devices, drugs, biologics, and combination products. Particular emphasis is placed on distinct frameworks for Class I, II, and III devices, as well as regulations for drugs, biologics, and combination products. The organizational structure of the FDA is detailed, with highlights on specific Ophthalmology oversight divisions, historical regulatory evolution, and initiatives such as Patient-Focused Drug Development. An in-depth examination of the regulatory journey, ranging from initial research to post-marketing surveillance, includes practical guidance through stages such as Pre-Investigational New Drug/Pre-Submission consultations, clinical trials, new drug application/biologics license application/premarket approval submissions, and FDA advisory committee interactions. The article underscores the importance of early interactions with the health authorities, interdisciplinary team collaboration, adherence to current standards, and the anticipation of policy changes to ensure patient safety. It concludes with an analysis of 4 key FDA-approved ophthalmic products, including Eylea®, Luxturna®, Alphagan P®, and the Raindrop® Near Vision Inlay, detailing their contributions to ophthalmic care and offering valuable insights into their respective clinical trials, regulatory pathways, and potential implications. These case studies are included to illustrate both successful and failed ophthalmic product launches, thereby highlighting the importance of alignment with regulatory compliance | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a FDA | |
| 650 | 4 | |a age-related macular degeneration | |
| 650 | 4 | |a inherited retinal dystrophies | |
| 650 | 4 | |a ophthalmic therapeutics | |
| 650 | 4 | |a regulatory process | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 700 | 1 | |a Bansinath, Mylarrao |e verfasserin |4 aut | |
| 700 | 1 | |a Mittal, Rahul |e verfasserin |4 aut | |
| 700 | 1 | |a Lemos, Joana R N |e verfasserin |4 aut | |
| 700 | 1 | |a Adis, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Poojari, Priyanka |e verfasserin |4 aut | |
| 700 | 1 | |a Igoe, Jane Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Soares, Marcio R |e verfasserin |4 aut | |
| 700 | 1 | |a Bhattacharya, Sanjoy |e verfasserin |4 aut | |
| 700 | 1 | |a Weiss, Roy E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics |d 1998 |g 39(2023), 8 vom: 03. Okt., Seite 572-582 |w (DE-627)NLM085101974 |x 1557-7732 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2023 |g number:8 |g day:03 |g month:10 |g pages:572-582 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/jop.2023.0071 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2023 |e 8 |b 03 |c 10 |h 572-582 | ||